Abstract It is becoming increasingly clear that mitochondrial dysfunction is critically important in myocardial ischemic injury, and that cardioprotective mechanisms must ultimately prevent or attenuate mitochondrial damage. Mitochondria are also essential for energy production, and therefore prevention of mitochondrial injury must not compromise oxidative phosphorylation during reperfusion. This review will focus on one mitochondrial mechanism of cardioprotection involving inhibition of adenine nucleotide transport across the outer mitochondria membrane under de-energized conditions. This slows ATP hydrolysis by the mitochondria, and would be expected to lower mitochondrial membrane potential during ischemia, to inhibit calcium uptake during ischemia, and potentially to reduce free radical generation during early reperfusion. Two interventions that similarly inhibit mitochondrial adenine nucleotide transport are Bcl-2 overexpression and GSK inhibition. A possible final common mechanism shared by both of these interventions is discussed.
Introduction
Since the original discovery of the cardioprotective effects of ischemic preconditioning in 1986 [1] , one of the unsolved mysteries of the phenomenon is the mechanism that is responsible for the energy sparing effect. It was recognized very early that during the sustained period of ischemia, ATP utilization was much slower in the preconditioned myocardium than in the non-preconditioned myocardium [2, 3] . This was recognized as a slower rate of decline in tissue ATP during ischemia, but the effect is even more pronounced if the total rate of ATP utilization is considered, which includes the ATP generated from anaerobic glycolysis during ischemia as well as the creatine phosphate and ATP present in the tissue at the start of ischemia. As shown in Fig. 1 , this energy sparing effect is present in both dog and rat myocardium. The energy sparing effect is apparent within the first 5 min of ischemia (Fig. 2) . The slower rate of ATP utilization results in less stimulation of anaerobic glycolysis, attenuates the fall in intracellular pH, and minimizes the ionic alterations that are characteristic of ischemia [3] . However, it is unlikely that ATP preservation is a major factor in the protective effect, because there is loss of ATP during the preconditioning protocol, and therefore less ATP reserves in the tissue at the start of the sustained period of ischemia; despite slower ATP utilization, ATP depletion occurs after a similar duration of ischemia in preconditioned and nonpreconditioned myocardium [2, 3] . In fact, the onset of contracture, which is a marker of severe ATP depletion, occurs more rapidly with some protocols of preconditioning in rodent hearts, which are none-the-less protected from ischemic injury [3, 4] . Therefore, if the energy-sparing effect of preconditioning is important for the protective effect, it is likely through an indirect mechanism.
Mitochondrial mechanisms of cardioprotection
We have found two cardioprotective interventions that target the mitochondria and are associated with an energy-conserving effect. These two interventions may help to illuminate the basis for the energy conserving effect, and potentially may point to a mechanistic basis for their cardioprotective effects. The first intervention is overexpression of Bcl-2 [5] and the second intervention is treatment with glycogen synthase kinase (GSK) inhibitors [5, 6] . Both of these interventions are associated with a reduction in the amount of cell death that occurs during a defined period of ischemia, and both of these interventions are associated with an alteration in mitochondrial transport that may account for the energy-conserving effect. The protective effect of GSK inhibitors is seen whether the inhibitor is administered prior to ischemia or at the onset of reperfusion and is observed in both isolated heart models and in vivo [7] [8] [9] . Studies of mice with cardiac-specific overexpression of Bcl-2 [5] showed that ATP consumption during the first few minutes of ischemia was slower than in wild-type hearts, and the fall in intracellular pH was less in the Bcl-2 overexpressor hearts. Previous work has shown that reversal of the mitochondrial F1F0ATPase is responsible for approximately 50% of ATP consumption during ischemia and that slowing this process slows the rate of anaerobic glycolysis [10] [11] [12] , resulting in less intracellular acidification. To determine whether Bcl-2 overexpression slows mitochondrial ATP hydrolysis under de-energized conditions, isolated mitochondria were de-energized with the uncoupler dinitrophenol, and the rate of mitochondrial ATP hydrolysis was found to be markedly slower in mitochondria with high levels of Bcl-2, either from Bcl-2 overexpressor hearts where the Bcl-2 remained associated with the mitochondria, or from wild-type hearts where recombinant Bcl-2 was added to the mitochondria. One possible explanation for this finding would be inhibition of anion transport through VDAC under de-energized conditions, and co-immunoprecipitation experiments were performed to show that Bcl-2 binds to VDAC. Furthermore, the amount of Bcl-2 that binds to VDAC is increased during ischemia [5] .
Since other cardioprotective interventions also have an energy conserving effect [13, 14] , it is possible that Bcl-2 overexpression is only one of several possible mechanisms that can affect mitochondrial ATP consumption under deenergized conditions. To investigate this possibility, we studied another intervention, which may be more closely linked to ischemic preconditioning, which is GSK inhibition. We [6, 7] and others [8, 15] have shown that GSK inhibition occurs during ischemic preconditioning and various forms of pharmacological preconditioning. Although recent studies with genetically altered mice have questioned the requirement for GSK inhibition in cardioprotection [16] , the bulk of data support a role for GSK [7, 8, 15, 17, 18] Fig. 1 Total amount of high-energy phosphate consumed in severely or totally ischemic myocardium during 20 min of ischemia. The total amount of high energy phosphate consumed is equal to the amount of ATP produced by anaerobic glycolysis and the amount of high energy phosphate that is derived from tissue reserves of ATP and creatine phosphate. For this calculation, it was assumed that the flux through anaerobic glycolysis is equal to the change in tissue lactate and that the lactate came from glycogen, which yield 1.5 high-energy phosphates per lactate. Creatine phosphate breakdown yields 1 high energy phosphate, ATP yields 2, and ADP yields 1. This calculation is described in more detail in Murry et al. [1] , and the data for the dog heart is taken from the same source. Data for the isolated rat heart was obtained from analysis of tissue extracts, using the same assays as for the dog heart. For both the dog and rat experiments, preconditioning consisted of four cycles of 5 min of ischemia and 5 min of reperfusion Fig. 2 The data are obtained from Murry et al. [1] , as described in Fig. 1 . The value at each time point is obtained from the changes in lactate, ATP, ADP, and creatine phosphate. The value for 2.5 min reflects the difference from time 0 to 5 min of ischemia. The value for 7.5 min reflects the difference from 5 to 10 min of ischemia, and the value for 15 min reflects the difference from 10 to 20 min of ischemia. The data are replotted from Fig. 12 of Murry et al. [1] altered mice [17] . We wanted to determine if the protection we observed with GSK inhibitors was associated with a mitochondrial energy-conserving effect similar to the effect of Bcl-2 overexpression. We used two different GSK inhibitors and pretreated isolated perfused rat hearts with the inhibitors [6] . We chose concentrations of inhibitors that attenuated ischemic injury. We isolated mitochondria from control hearts and hearts treated with GSK inhibitors, and we studied mitochondrial ATP consumption under deenergized conditions. We used the same de-energization protocol that we used for the Bcl-2 experiments (the uncoupler dinitrophenol), and we used two other protocols that would be more analogous to ischemic conditions. These other protocols involved treating the mitochondria with cyanide to block respiration and making the mitochondria anoxic by having them consume the oxygen in a sealed oxygraph chamber. These protocols prevent mitochondrial respiration but do not immediately de-energize the mitochondria, and therefore the duration of treatment was extended to allow the mitochondria to become deenergized. As shown in Fig. 3 , regardless of the protocol, we found that ATP hydrolysis by the isolated mitochondria was slower in the mitochondria from hearts treated with GSK inhibitors than in control mitochondria. The finding that Bcl-2 and GSK inhibitors slow ATP hydrolysis by de-energized mitochondria does not clarify the site of the inhibitory effect. The assay is based on addition of ATP to the medium, and the measurement of the amount of ATP remaining at the end of incubation. Inhibition of ATP transport through the voltage-dependent anion channel (VDAC) in the outer mitochondrial membrane), inhibition of ATP transport through the adenine nucleotide translocator (ANT) in the inner mitochondrial membrane, or inhibition of the F1F0ATPase in the mitochondrial matrix could account for the energy-conserving effect of these cardioprotective interventions. To clarify the site of the inhibitory effect, we sonicated the mitochondria to disrupt the membranes and expose the F1F0ATPase, and we found that GSK inhibitors do not affect ATP hydrolysis in the sonicated mitochondrial fragments [6] , indicating that the GSK inhibitors are not affecting F1F0ATPase activity. It is also possible that ATP hydrolysis does not involve the physiologic adenine nucleotide transporters, but rather involves the mitochondrial permeability transition pore (mPTP), and multiple investigators have proposed that inhibition of mPTP opening is an important element of many cardioprotective interventions [15, [19] [20] [21] [22] . To evaluate this, we treated the mitochondria with cyclosporine A, at a concentration which inhibits calciuminduced swelling, and we saw no effect of cyclosporine A on ATP hydrolysis in either control mitochondria or mitochondria treated with a GSK inhibitor. Finally, we used an assay that would distinguish between transport across the outer mitochondrial membrane through VDAC versus transport across the inner mitochondrial membrane through ANT. As shown in Fig. 4 , this assay takes advantage of the enzyme adenylate kinase which is located in the intermembrane space. Isolated mitochondria are treated with cyanide to block respiration and de-energize the mitochondria, and oligomycin was added to block the F1F0ATPase. After 20 min of incubation to allow the mitochondria to become de-energized, ADP was added to the medium. ADP can enter the intermembrane space through VDAC, where it can be converted by adenylate kinase to ATP and AMP, which can then exit the mitochondrial outer membrane through VDAC. This assay measures the rate of adenine nucleotide transport through VDAC and the rate of conversion of ADP to ATP and AMP by adenylate kinase. We measured both the amount of ADP remaining in the medium and the amount of AMP that was present in the medium 10 min after ADP addition. Figure 5 shows that ADP consumption and AMP production were reduced in the GSK inhibitor treated mitochondria to a similar extent. To be certain that the GSK inhibitors were not altering adenylate kinase activity, mitochondria were sonicated and the same assay was performed. Under these conditions, there was no effect of GSK inhibitors [6] , and the rate of AMP production in the control and GSK inhibitor treated mitochondrial fragments was comparable to the control intact mitochondria.
Mitochondrial targets of cardioprotective interventions
These data suggest that GSK inhibition alters anion transport through the outer mitochondrial membrane under deenergized conditions. Since GSK is a kinase, it is possible that the mechanism of the inhibitory effect on transport is related to a phosphorylation event. As an initial screen for phosphorylation differences between control and GSK inhibitor-treated myocardium, whole tissue extracts were prepared and proteins were separated and evaluated by western blotting using an antibody that recognizes proteins that are phosphorylated at Akt sites. We found that this antibody identified a protein at *32 kDa that was highly phosphorylated in control myocardium and there was virtually no detectable phosphorylated protein at this molecular weight in myocardium treated with GSK inhibitors [6] . Using 2D gels, we found that this protein stained with antibodies to VDAC, and we used mass spectrometry to confirm that VDAC was present in the spots. Thus it appears that VDAC is phosphorylated by a GSK dependent mechanism; GSK-3beta is normally active and VDAC is normally present in the phosphorylated form. In the presence of GSK inhibitors, VDAC is primarily in the nonphosphorylated form. Figure 6 shows several possible mechanisms that could explain these findings. The data would be consistent with direct phosphorylation of VDAC by GSK-3beta. GSK3beta is normally active and therefore VDAC would be phosphorylated at baseline. When GSK is inhibited either by phosphorylation such as during preconditioning or by use of inhibitors, VDAC phosphorylation stops and the phosphatase dephosphorylates VDAC. An alternative mechanism would be that Akt phosphorylates VDAC and GSK regulates the phosphatase that dephosphorylates VDAC. There is a basal level of Akt activity, which could be sufficient to maintain VDAC in a phosphorylated state if the phosphatase activity was inhibited by GSK. In this case, inhibition of GSK, by either phosphorylation or pharmacological inhibitors, removes the inhibitory effect of GSK on the phosphatase that dephosphorylates VDAC, phosphatase activity now exceeds Akt activity, and VDAC is primarily in the dephosphorylated state. The third possibility is that there could be more than one phosphorylation site. This is an attractive concept since GSK-3beta is known to prefer primed substrates [23] . If Akt is responsible for the initial phosphorylation and GSK-3beta was responsible for the second phosphorylation, then it would be expected that the basal level of Akt activity and the high basal GSK-3beta activity would result in VDAC in the phosphorylated state at baseline. It could be that the second phosphorylation is necessary to protect the initial phosphorylation from phosphatase activity. When GSK is inhibited, then the phosphatase would be able to dephosphorylate VDAC. Although the third mechanism is the most attractive, the data do not distinguish between these possibilities. To assess whether Akt or GSK-3beta can phosphorylate VDAC, we partially purified VDAC and assessed whether recombinant active Akt or GSK-3beta could phosphorylate VDAC, and we found evidence that both kinases were capable of phosphorylating the isolated protein [6] . Whether either or both kinases phosphorylate VDAC in situ remains to be determined. Finally, it was intriguing that Bcl-2 overexpression and GSK inhibition have a very similar effect on mitochondrial adenine nucleotide metabolism under de-energized conditions, which raises the possibility that there could be synergism between Bcl-2 and GSK-regulated VDAC phosphorylation. One possibility would be that Bcl-2 binding to VDAC under de-energized conditions alters anion transport through VDAC, and the critical level of Bcl-2 binding might be achieved either by overexpressing Bcl-2 or by increasing the affinity of VDAC for Bcl-2. Although it is possible that VDAC phosphorylation status directly alters anion transport, it is also possible that phosphorylation alters the binding between Bcl-2 and VDAC. For example, in non-cardiac cells, inhibition of GSK results in decreased phosphorylation of VDAC, which leads to decreased binding of hexokinase to VDAC and reduced cell death [24] . To address the possibility that VDAC phosphorylation affects Bcl-2 binding, we looked for evidence that binding of Bcl-2 to VDAC would be increased under conditions where VDAC would be dephosphorylated [6] . We found evidence that Bcl-2 translocated to the mitochondria in hearts treated with GSK inhibitors, and we found that the amount of Bcl-2 that coimmunoprecipitates with VDAC is increased in the presence of a GSK inhibitor. These results are consistent with the hypothesis that increased Bcl-2 binding to VDAC may be involved in the effects of GSK inhibitors on adenine nucleotide transport through VDAC under de-energized conditions, but proof that this is the most important mechanism will require more experimentation.
Role of VDAC in cell injury
The previous discussion postulates a critical role for VDAC regulation in ischemia/reperfusion injury. VDAC is the most abundant protein of the outer mitochondrial membrane and is responsible for most of the metabolite exchange between the cytosol and intermembrane space [25] . Thus this channel is vital for normal cell function, particularly for an organ that depends on oxidative phosphorylation for energy to support normal function, such as the heart. There are three known isoforms of VDAC in mammalian cells [26] . Genetic manipulation approaches have been used to study the role of different VDAC isoforms in basal cell function and under pathologic conditions. It has been found that ablation of the VDAC1 or VDAC3 gene is consistent with normal development, whereas loss of VDAC2 is embryologically lethal. VDAC1 and VDAC3 null mice are not protected against ischemiareperfusion injury [27] , but normal development implies that adenine nucleotide transport across the outer mitochondrial membrane is adequate to maintain energy balance, and our results suggest that VDAC2 may be the critical element in altered adenine nucleotide transport under de-energized conditions, which was not altered in either of the knockout mice. Fibroblasts lacking all three VDAC isoforms demonstrate unaltered calcium-induced and oxidative-stress-induced mPTP opening and cell death compared to wild-type [27] . This suggests that VDAC may not be an obligatory component of the mPTP. However, fibroblasts do not have the same rates of energy utilization as adult cardiac myocytes, and the results with fibroblasts may not be directly applicable to adult cardiac myocytes. Nevertheless, it would be instructive to study mitochondrial adenine nucleotide transport in mitochondria from these cells.
Role of VDAC and Bcl-2 in apoptosis
Much work on VDAC regulation and cell function has focused on the role of VDAC in modulation of apoptosis signaling, particularly apoptosis signaling involving Bcl-2 family members. It has been suggested that VDAC is a binding partner for several proteins that may play a role in apoptosis including Bcl-2 family members and hexokinase I and II [28] , and that protein binding is regulated by protein kinases, including GSK-3beta and PKCepsilon. VDAC1 can also be phosphorylated by Nek1, which results
in protection against cell death following DNA damage [29] . VDAC1 phosphorylation has also been linked to p38 MAP kinase activity, and inhibition of this phosphorylation with p38 inhibitors is cardioprotective [30] . VDAC phosphorylation by GSK-3beta promotes detachment of hexokinase II from VDAC1 [24] . In contrast, VDAC phosphorylation by PKCepsilon promotes hexokinase binding [31] . A recent mass spectrometry study suggests that there are multiple post-translational modifications of VDAC and phosphorylation sites on all three VDAC isoforms [32] , and therefore multiple mechanisms of VDAC regulation are possible. However, there is evidence that VDAC2 does not directly interact with hexokinase I or II [33] . The role of hexokinase binding to VDAC1 in apoptosis has been questioned by the finding that a peptide that dissociates hexokinase from VDAC1 is effective in inducing apoptosis in fibroblasts lacking VDAC1 [33] , similar to its effect in wild-type cells.
Multiple models have been suggested of the role of hexokinase binding in apoptosis. Hexokinase may compete with Bcl-2 family members for VDAC binding sites, and release of hexokinase from these binding sites could result in sequestration of anti-apoptotic Bcl-2 family members, making them unavailable for anti-apoptotic functions [28] . VDAC1 may not be the only binding site as suggested by the results from VDAC1 null cells [33] . It has also been suggested that Akt promotes the association between hexokinase and mitochondria [34] , and Miyamoto et al. [35] has shown that Akt mediates this effect through phosphorylation of hexokinase II. Furthermore, phosphorylation of hexokinase II by Akt is associated with protection of the mitochondria against oxidant or calciuminduced mPTP opening.
Altered VDAC function and cell injury
Multiple investigators have suggested that VDAC can be an important regulator of mitochondrial function. Under anoxic conditions, there is evidence that mitochondrial anion transport can become inhibited [36] . There is also evidence that VDAC function is altered under conditions leading to apoptosis. It has been suggested that early in the induction of apoptosis, VDAC permeability to anions such as creatine phosphate and ATP is reduced [37] . Under these conditions, mitochondria are aerobic and generating ATP, and inhibition of anion transport through VDAC would not affect mitochondrial energetics but would impair delivery of high energy phosphates to the cytosol to maintain cellular functions. This is thought to eventually lead to loss of outer mitochondrial membrane integrity and cytochrome c release, which can be prevented by anti-apoptotic Bcl-2 family members [38] . The role of Bcl-2 family members in VDAC regulation under conditions of apoptosis is controversial, and another group suggests Bcl-2 promotes VDAC closure [39] . This difference could be related to different experimental conditions or to measurement at different times in the evolution of apoptosis, but the data all support the concept that VDAC can be regulated under conditions of cell injury.
Role of altered mitochondrial adenine nucleotide transport in myocardial ischemia/reperfusion injury Numerous investigators have implicated a variety of cytosolic signaling cascades in the cardioprotective effect of ischemic preconditioning, and have shown that these signaling cascades can be activated by pharmacologic agents, which stimulate the same pathways (see for example [40, 41] . What is less clear is the downstream targets of these signaling pathways, with the exception that opening of the mPTP appears to be a final common mechanism of cell death [20, 42, 43] . The finding that GSK inhibitors slow adenine nucleotide transport across the outer mitochondrial membrane, presumably through VDAC, suggests a molecular target for GSK regulation. GSK inhibition is a feature of many cardioprotective interventions [15] , and thus this mechanism of altered VDAC transport may be a general feature of many forms of cardioprotection. Furthermore, this inhibitory effect on VDAC transport occurs prior to opening of the mPTP and thus is not likely due to inhibition of mPTP opening directly, but it may be protective by indirectly limiting mitochondrial injury under de-energized conditions. During ischemia, anaerobic glycolysis generates ATP in the cytosol. If this ATP crosses the outer mitochondrial membrane, it can be taken up into the mitochondrial matrix and hydrolyzed by the F1F0-ATPase, which can slow the fall in membrane potential during ischemia. Several investigators have demonstrated that inhibition of this process results in a more rapid decrease in mitochondrial membrane potential [11, 44] . Since mitochondrial membrane potential provides the driving force for calcium uptake by the mitochondria, it is likely that lowered mitochondrial membrane potential would result in less mitochondrial matrix calcium accumulation, and this has been observed in isolated myocytes subjected to simulated ischemia [44] . Alternatively, a reduction in mitochondrial membrane potential due to slowing of VDAC transport of adenine nucleotides under ischemic conditions could result in less oxygen radical production during early reperfusion. Either a reduction in matrix calcium or a reduction in oxygen radical generation would be protective by decreasing the stimulus for mPTP opening, and would be consistent with findings from other laboratories that inhibition of mPTP opening is critical for cardioprotection.
Role of other molecular targets of Bcl-2 or GSK inhibition
The effect of Bcl-2 overexpression on ischemia-reperfusion injury may not be limited to an effect on adenine nucleotide transport during the early phase of ischemic injury. Bcl-2 may be interacting with multiple components of the mPTP and may be suppressing mPTP opening by multiple mechanisms. The precise composition of the mPTP is unknown, and genetic ablation studies have clearly shown that none of the VDAC isoforms are obligatory [27] . Similarly, GSK has many targets, and VDAC is not the only target that may be important in ischemia-reperfusion injury. Other targets have been discussed elsewhere [23, 45] , and GSK inhibition may be protective through modulation of the phosphorylation of several downstream substrates.
Summary and conclusions
The ability of several different cardioprotective interventions to induce an energy-sparing effect during ischemia is linked to reduced mitochondrial ATP hydrolysis, which is related to inhibition of adenine nucleotide transport across the outer mitochondrial membrane when the mitochondria are de-energized. These cardioprotective interventions include ischemic preconditioning, Bcl-2 overexpression, and GSK inhibition. These interventions may share a common mechanistic pathway involving altered protein binding to VDAC which regulates VDAC function, and one mechanism that regulates protein binding appears to be VDAC phosphorylation. The finding that several cardioprotective interventions alter adenine nucleotide transport across the outer mitochondrial membrane, through VDAC, suggests that outer mitochondrial membrane transport may be an important site of metabolic regulation under deenergized conditions, which may contribute to the protective effects of these interventions. The finding that this mechanism is present in several different cardioprotective interventions suggests the possibility that this may be a general mechanism of cardioprotection, but this hypothesis remains to be proven.
